These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29582233)

  • 21. Substance abuse in adolescents before admission to Peruvian juvenile detention centers: results from a national census in Peru, 2016.
    Vargas-Fernández R; Rojas-Roque C; Santero M; Runzer-Colmenares FM; Figueroa W
    Int J Adolesc Med Health; 2019 Dec; 34(3):. PubMed ID: 31800391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of a prerelease substance abuse treatment program for repeat criminal offenders.
    French MT; Fang H; Fretz R
    J Subst Abuse Treat; 2010 Jan; 38(1):31-41. PubMed ID: 19631489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of public health agencies in providing access to adolescent drug treatment services.
    VanderWaal CJ; McBride DC; Terry-McElrath YM; Bishop RM
    J Adolesc Health; 2006 Dec; 39(6):916-24. PubMed ID: 17116524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The economic impact of multisystemic therapy through midlife: a cost-benefit analysis with serious juvenile offenders and their siblings.
    Dopp AR; Borduin CM; Wagner DV; Sawyer AM
    J Consult Clin Psychol; 2014 Aug; 82(4):694-705. PubMed ID: 24684692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion.
    Heslin M; Patel A; Stahl D; Gardner-Sood P; Mushore M; Smith S; Greenwood K; Onagbesan O; O'Brien C; Fung C; Ohlsen R; Hopkins D; Lowe P; Arbuthnot M; Mutatsa S; Todd G; Kolliakou A; Lally J; Stubbs B; Ismail K; David A; Murray R; Atakan Z; Gaughran F
    BMC Psychiatry; 2017 Dec; 17(1):407. PubMed ID: 29273021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021.
    Fardone E; Montoya ID; Schackman BR; McCollister KE
    J Subst Use Addict Treat; 2023 Sep; 152():209084. PubMed ID: 37302488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Service costs of caring for adolescents with mental illness in a rural community, 1993-2000.
    Costello EJ; Copeland W; Cowell A; Keeler G
    Am J Psychiatry; 2007 Jan; 164(1):36-42. PubMed ID: 17202542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Juvenile drug court: enhancing outcomes by integrating evidence-based treatments.
    Henggeler SW; Halliday-Boykins CA; Cunningham PB; Randall J; Shapiro SB; Chapman JE
    J Consult Clin Psychol; 2006 Feb; 74(1):42-54. PubMed ID: 16551142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Los Angeles County drug court programs: initial results.
    Fielding JE; Tye G; Ogawa PL; Imam IJ; Long AM
    J Subst Abuse Treat; 2002 Oct; 23(3):217-24. PubMed ID: 12392808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Juvenile drug courts: emerging outcomes and key research issues.
    Henggeler SW
    Curr Opin Psychiatry; 2007 May; 20(3):242-6. PubMed ID: 17415076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation.
    Hayhurst KP; Leitner M; Davies L; Flentje R; Millar T; Jones A; King C; Donmall M; Farrell M; Fazel S; Harris R; Hickman M; Lennox C; Mayet S; Senior J; Shaw J
    Health Technol Assess; 2015 Jan; 19(6):1-168, vii-viii. PubMed ID: 25619533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-benefit and cost-effectiveness analysis of drug abuse treatment services.
    Cartwright WS
    Eval Rev; 1998 Oct; 22(5):609-36. PubMed ID: 10186896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and costs associated with mutual-help community-based recovery homes: The Oxford House model.
    Lo Sasso AT; Byro E; Jason LA; Ferrari JR; Olson B
    Eval Program Plann; 2012 Feb; 35(1):47-53. PubMed ID: 22054524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-benefit analysis of multisystemic therapy with serious and violent juvenile offenders.
    Klietz SJ; Borduin CM; Schaeffer CM
    J Fam Psychol; 2010 Oct; 24(5):657-66. PubMed ID: 20954776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Juvenile justice and substance use.
    Chassin L
    Future Child; 2008; 18(2):165-83. PubMed ID: 21338002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organizational structure, climate, and collaboration between juvenile justice and community mental health centers: implications for evidence-based practice implementation for adolescent substance use disorder treatment.
    Johnson-Kwochka A; Dir A; Salyers MP; Aalsma MC
    BMC Health Serv Res; 2020 Oct; 20(1):929. PubMed ID: 33032587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Juvenile drug treatment courts in the United States: initial lessons learned and issues being addressed.
    Cooper CS
    Subst Use Misuse; 2002; 37(12-13):1689-722. PubMed ID: 12487239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the effectiveness and cost-effectiveness of drug intervention programs: UK case study.
    Collins BJ; Cuddy K; Martin AP
    J Addict Dis; 2017; 36(1):5-13. PubMed ID: 27135713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.